

VRL/SEC/EXCHANGE

Dated:13.09.2023

<b>National Stock Exchange of India Ltd.</b> 5 <sup>th</sup> Floor, Exchange Plaza Bandra (E), <b>Mumbai- 400 051</b> <b>Script Code: VENUSREM</b>	<b>BSE Limited</b> 25 <sup>th</sup> Floor, Phiroze Jeejeebhoy Towers Dalal Street Mumbai <b>Script Code: 526953</b>
--	---

**Sub.: Press Release- Venus Remedies Limited attains the Department of Scientific and Industrial Research (DSIR) registration for Customs Duty Exemption.**


Dear Sir/ Madam,

Kindly find enclosed herewith is a press release being issued by the Company on the captioned subject.

Kindly take the above information on your record.

Thanking you.

Yours faithfully,  
for **VENUS REMEDIES LIMITED**

  
**Neha**  
(Company Secretary)



## **VENUS REMEDIES LIMITED**

**Corporate Office :**

51-52, Industrial Area, Phase- I, Panchkula (Hry.)  
134113, India

**Regd. Office :**

SCO 857, Cabin No. 10, 2nd Floor, NAC, Manimajra,  
Chandigarh (U.T.) 160101, India

Website : [www.venusremedies.com](http://www.venusremedies.com)

[www.vnrcindia.com](http://www.vnrcindia.com)

email : [info@venusremedies.com](mailto:info@venusremedies.com)

CIN No. : L24232CH1989PLC009705

**Unit-I :**

51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India  
Tel. : +91-172-2933090, 2933094, Fax : +91-172-2565566

**Unit-II :**

Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),  
Bhatoli Kalan, Baddi (H.P.) 173205, India  
Tel. : +91-1792-242100, 242101

**Unit-V :**

VENUS PHARMA GmbH  
AM Bahnhof 1-3, D-59368,  
Werne, Germany





## PRESS RELEASE

# **VENUS REMEDIES LIMITED ATTAINS THE DEPARTMENT OF SCIENTIFIC AND INDUSTRIAL RESEARCH (DSIR) REGISTRATION FOR CUSTOMS DUTY EXEMPTION**

- *One Of India's Top 20 R&D Spenders, VRL Receives Customs Duty Exemption By DSIR, Ministry Of Science & Technology, Government Of India*

**Chandigarh, September 13, 2023:** Venus Remedies Limited, a leading research-driven pharmaceutical company in India, proudly announces its recent registration with the Department of Scientific and Industrial Research (DSIR), Ministry of Science & Technology, Government of India. This significant milestone allows the company to avail customs duty exemption, reinforcing its commitment to innovation, excellence in research, and its substantial contributions to the healthcare sector.

This registration with DSIR exemplifies Venus Remedies Limited's dedication to fostering innovation and making healthcare solutions more accessible. With a strong track record of bringing 15 patented products to market and a robust pipeline of innovative pharmaceuticals, the company has consistently demonstrated a forward-thinking approach to drug development.

Mr. Saransh Chaudhary, CEO of Venus Medicine Research Centre at Venus Remedies, commented, "We are honored to receive this registration from DSIR, which reflects our unwavering commitment to advancing healthcare through cutting-edge research and development. This exemption will not only enable us to reduce production costs but also empower us to invest more in research and development, enhancing our competitiveness and expanding our global reach."

Venus Remedies Limited remains committed to delivering innovative and effective solutions to address healthcare needs on a global scale. The DSIR registration is a testament to the company's ongoing dedication to advancing healthcare through research and development.

### **About Venus Remedies**

Panchkula-based Venus Remedies Ltd (NSE: VENUSREM, BSE: 526953) is among the 10 leading fixed-dosage injectable manufacturers in the world. Having a commercial presence in 70+ countries with a portfolio of 75 products spread over Europe, Australia, Africa, Asia-Pacific, Commonwealth States, the Middle East, Latin America and the Caribbean region, the company has nine globally benchmarked facilities in Panchkula, Baddi



and Werne (Germany), apart from 11 overseas marketing offices. Its manufacturing units are certified for ISO 9001, ISO 14001, ISO 18001 and OHSAS. The company has also been approved by European- GMP, WHO-GMP and Latin American GMP (INVIMA), among others. Ranked 107th in Asia and among the world's 500 largest pharmaceutical manufacturing companies, Venus Remedies has been granted more than 130 patents worldwide and having more than 125 registered trademarks and 25 copyrights for its innovative research products.

